About Axial
Axial is a venture capital firm founded in 2019. It is primarily based out of San Francisco, United States. As of May 2025, Axial has invested in 12 companies. It primarily invests in Seed round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and Environment Tech. Most recently it participated in the $***** Seed round of Stately Bio Overall, Axial portfolio has seen 1 acquisition, namely Replay. A lot of funds co-invest with Axial, with names like Civilization Ventures sharing a substantial percentage of its portfolio. Axial has team of 1 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed & Series A
Portfolio Acquisitions
Axial's List of Top Investments
Axial has a portfolio of 12 companies. Their most notable investments include Think Bioscience and Rubi.Their portfolio spans across United States and Australia. They have invested in Life Sciences, Enterprise Applications, Environment Tech and 6 other sectors, across stages such as Seed, Series A stages. Here is the list of top investments by Axial:
Provider of synthetic biology platform to develop small-molecule therapeutics. The company's platform combines applied microbiology, enzymology, and data science to develop medicines against difficult-to-drug proteins.
Key facts about Think Bioscience
- Founded Year: 2019
- Location: Boulder (United States)
- Stage: Series A
- Total Funding till date: $26M
- Employee Count: 32 as on Sep 30, 2026
- Investors: Janus Henderson Investors, Crescent Enterprises and 12 Others
- Latest Funding Round: Series A, Jan 20, 2026, $*****
- Highlight: Editors' Pick
2. Rubi
Manufacturer of biobased textiles made from captured carbon emissions. The company’s process removes carbon dioxide from the atmosphere. It creates textiles using virtually zero water and land. The textiles are the same material already used in apparel. The material biodegrades at the end of its life. The technology uses enzymes to convert carbon dioxide to cellulose.
Key facts about Rubi
- Founded Year: 2020
- Location: San Francisco (United States)
- Stage: Series A
- Total Funding till date: $25.8M
- Employee Count: 27 as on Sep 30, 2026
- Investors: Collab Fund, Kayak Ventures and 26 Others
- Latest Funding Round: Series A, Nov 21, 2025, $*****
- Highlight: Editors' Pick
3. Infinimmune
Developer of antibody-based drugs to treat various diseases. The company is pioneering antibody drug discovery and development focusing solely on human-derived antibody drugs for high-impact fields like an infectious disease, autoimmune diseases, and immuno-oncology.
Key facts about Infinimmune
- Founded Year: 2022
- Location: Alameda (United States)
- Stage: Series A
- Total Funding till date: $87M
- Employee Count: 24 as on Sep 30, 2026
- Investors: RA Capital Management, Goldcrest and 13 Others
- Latest Funding Round: Series A, Aug 11, 2026, $*****
- Highlight: Editors' Pick
4. Replay
Provider of genomic reprogramming platform for writing and delivering big DNA. It offers proprietary technology platforms, synHSV - a high payload capacity HSV vector able to deliver up to 30x the payload of AAV, uCell - a universal, renewable, off-the-shelf, genomically rewritten, hypoimmunogenic iPSC-derived cell source for regenerative medicine and cell therapy, DropSynth - a genome writing platform, LASR inference algorithm platform for rewriting proteins to optimize the functionality.
Key facts about Replay
- Founded Year: 2021
- Location: San Diego (United States)
- Stage: Acquired
- Total Funding till date: $55M
- Employee Count: 30 as on Sep 30, 2026
- Investors: Lansdowne Partners, Artis Ventures and 6 Others
- Latest Funding Round: Grant (prize money), Nov 28, 2022, $*****
- Highlight: Acquired
Developer of a platform for next-generation protein sequencing. The company is decoding the human proteome through de novo protein sequencing at single-molecule resolutions that enable researchers to gain novel insights into biology and disease.
Key facts about Glyphic Biotechnologies
- Founded Year: 2021
- Location: San Francisco (United States)
- Stage: Series A
- Total Funding till date: $39.2M
- Employee Count: 34 as on Sep 30, 2026
- Investors: Wing Venture Capital, Artis Ventures and 10 Others
- Latest Funding Round: Grant (prize money), Feb 28, 2025, $*****
- Highlight: Editors' Pick
Axial's Year-on-Year Investment Trends
Axial has invested in 12 companies over the last 5 years, with an average of 2 new investments annually in the last 5 years. In 2025, it made 1 investment. Its most recent first time investment was in Stately Bio.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 1 | 0 | 1 |
2024 | 1 | 0 | 1 |
2023 | 3 | 0 | 3 |
2022 | 5 | 0 | 5 |
2021 | 2 | 0 | 2 |
Axial's Investments by Stage
Axial has made 10 investments in Seed stage with an average round size of $13.1M and 2 investments in Series A stage with an average round size of $36M.Stage of entry | No. of Investments |
|---|---|
Seed | 10 |
Series A | 2 |
Note: We have considered here, only first round of investments
Axial's Investments by Sector
Axial has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, HealthTech, High Tech and Healthcare. Notably, it has invested in 10 Enterprise (B2B) companies, 10 Tech companies, 5 Software companies and at least 2 companies focusing on Saas.Sector | No. of Investments |
|---|---|
Life Sciences | 8 |
Enterprise Applications | 5 |
HealthTech | 4 |
High Tech | 3 |
Healthcare | 2 |
Others | 8 |
Note: We have considered here, only first round of investments
Axial's Investments by Geography
Axial has made most investments in United States (12), followed by Australia where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 12 |
Australia | 1 |
Note: We have considered here, only first round of investments
Axial's recent investments
Axial has not made any investment in 2026 so far.Here are the most recent investments by Axial:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 01, 2025 | United States | Seed | 2581 | [+9] | |
Oct 28, 2024 | United States | Seed | 9513 | [+4] | |
Dec 19, 2023 | United States | Seed | 3420 | [+4] | |
Nov 29, 2023 | United States | Seed | 8174 | [+2] | |
Feb 28, 2023 | United States | Series A | 1348 |
Acquired companies in Axial's Portfolio
1 company from Axial's portfolio has been acquired. The most recent acquisition was Replay in Apr 2026 by LEO Pharma for $*****.Here are Axial's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 30, 2026 | Jul 25, 2022 | Seed | 2438 |
Team profile of Axial
Axial has a team of 1 member located in United States. Axial's team does not sit on the board of any company as of now.Co-investors of Axial
Over the past 5 years, 118 investors have co-invested in Axial's portfolio companies. This includes funds and angels.
- Invested before Axial: America’s Seed Fund, Y Combinator and 4 others have invested in rounds before Axial. There is 1 company where America’s Seed Fund has invested before Axial and 1 company where Y Combinator has invested before Axial.
- Top Co-investors of Axial: 79 investors entered a company along with Axial. These include investors like Civilization Ventures (4 companies).
- Invested after Axial: A total of 33 investors have invested in Axial's portfolio after their investments. Top Investors include Regeneron Ventures (2 companies), Janus Henderson Investors (1 company) and MBX Capital (1 company).
Recent News related to Axial
•
Infleqtion Secures $100M to Scale Quantum PlatformsFinSMEs•Jun 02, 2025•Infleqtion, Glynn Capital, S32, SAIC Capital and 11 others
•
Stately Bio Raises $12M in Seed FundingFinSMEs•May 01, 2025•Stately Bio, AIX Ventures, Dimension, Foothill Ventures and 5 others
•
Insamo Launches with $12M Funding from Playground Global, venBio, and MRL Ventures Fund to Develop Best-in-Class Membrane-Permeable Macrocyclic PeptidesBusiness Wire•Feb 21, 2024•Insamo, Playground, VenBio, MRLV and 5 others
•
Aperiam Bio Raises $9 Million in Seed Funding to Revolutionize Protein EngineeringSilicon Valley Journals•Nov 29, 2023•Aperiam Bio, OMX Ventures, Axial, KdT Ventures and 1 other
•
Nalu Bio Raises $12M in Series A FundingFinSMEs•Feb 27, 2023•Nalu, Intrinsic Capital Partners, Flybridge Capital Partners, Portfolia and 7 others
•
Infinimmune Raises $12-Million Seed Funding to Design Drugs Using Human-Sourced AntibodiesGEN•Dec 06, 2022•Infinimmune, Playground, Pear VC, Civilization Ventures and 3 others
•
Meliora Therapeutics Raises $11M Seed Financing to Develop First Mechanism Of Action Atlas in OncologyBusiness Wire•Sep 29, 2022•Meliora Therapeutics, HOF Capital, Zhen Fund, Obvious Ventures and 6 others
•
Think Bioscience Raises $17M in Oversubscribed Seed Round to Develop Small Molecule Drugs that Hit Undruggable ProteinsGlobeNewswire•Aug 18, 2022•Think Bioscience, Innovation Endeavors, Xora Innovation, AV8 Ventures and 4 others
•
Synbio Company Replay Launches with $55M in Seed FundingGenomeWeb•Jul 25, 2022•KKR, OMX Ventures, Artis Ventures, Lansdowne Partners and 13 others
•
Rubi Laboratories pulls in $4.5m seedVCJ•Feb 17, 2022•Rubi, Talis Capital, Necessary Ventures, Climactic and 9 others
